Treating Advanced-Stage Lung Cancer with TKIs
Paul A. Bunn, Jr, MD, explains how patients with advanced-stage lung cancer benefit from tyrosine kinase inhibitors (TKIs)
Paul A. Bunn, Jr, MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, explains how patients with advanced-stage lung cancer benefit from tyrosine kinase inhibitors (TKIs)
Clinical Pearls
- Many patients have comorbid diseases and are very sick when they are diagnosed with lung cancer
- TKIs are oral, do not require an IV and they do not have grade 3 and 4 life-threatening toxicities
- Sick patients who have lung cancer should have molecular testing to see if they are eligible to use TKIs
Recent Videos
Related Content
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024Article
In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
